< Back to latest news & events

Knowledge Hub

EU SPC waiver for generic pharmaceuticals producers

May 2019

The awaited regulation which will introduce a “manufacturing waiver” for EU SPCs relating to medicinal products has been formally adopted by the EU Council and is expected to enter into force on 1 July 2019 (dependent on the date of publication of the Regulation in the EU’s Official Journal).

Broadly speaking, the regulation will introduce an exception to the protection granted to an original medicine by an SPC for export purposes and/or for stockpiling, provided that particular conditions are met.

Initially, the regulation will affect only SPCs that are applied for on or after the date of entry into force of the regulation. However, three years after the date of entry into force, the regulation will also affect SPCs applied for before that date, but which have become effective after that date.

In summary, the exception applies to:

  • manufacture of a product for the purposes of export to third countries (where protection of the original medicine does not exist or has expired) and to related acts which are strictly necessary for that manufacture or export; and
  • only in the last six months of validity of the SPC, manufacture of a product for the purposes of storing in the Member State of manufacture (in order to market the product in the EU after expiry of the SPC) and any related acts strictly necessary for that manufacture or storage.

The exception will only operate if certain conditions are met. For example, key requirements are that:

  • the maker (the person on whose behalf the relevant manufacture takes place) has provided certain information required by the regulation to both the authorities of the Member State of manufacture and to the SPC holder at least three months in advance of manufacture or an earlier related act;
  • the maker has duly informed others involved in the commercialisation of the product who are performing excepted acts; and
  • the maker has affixed to the packaging of the product the specific logo provided for by the regulation indicating clearly that it is only for export.

In its press release the Council said that “The regulation will remove the competitive disadvantages faced by EU-based manufacturers of generics and biosimilars vis-à-vis manufacturers established outside the EU in global markets.”

This update was prepared by Karen Russell, Senior Patent Attorney. If you have any queries about the regulation, please contact Karen. Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details
Event - 24th - 25th November 2025

HGF Partners with 3AF for the P2I2025 Symposium

HGF are pleased to be a partner of P2I2025, the annual symposium organised by the Intellectual Property Commission of the French Aeronautics and Astronautics Association (3AF). The event brings together …

Event details
Event - 18th November 2025

OIS Investor Forum - Jeffries

HGF is proud to be sponsoring the OIS Investor Forum on 18th November. One of the premier gatherings for leaders, innovators, and investors across the healthcare industry. The forum covers …

Event details
Event - 4th November 2025

HGF are Silver Sponsors of LSPN Europe 2025

HGF is proud to be a Silver Sponsor of LSPN Europe 2025, a leading forum dedicated to helping life sciences innovators protect and leverage their intellectual property across the entire …

Event details
Event - 30th - 31st October 2025

RAPS European Digital Technologies and Software conference

HGF is proud to be attending the RAPS European Digital Technologies and Software conference in The Netherlands on 30th-31st October. HGF Partner and Patent Attorney Janine Swarbrick and Patent Director …

Event details